OpenEvidence: The App That Answers Medical Questions in Seconds
A doctor walks into a complicated case. There are three medications involved. Two chronic conditions. A new lab result. A guideline that may have changed. And a question nobody has time to research for 45 minutes. Instead of opening five tabs, searching PubMed, checking a guideline, scanning a review article, and trying to reconcile conflicting evidence, the clinician asks a question in OpenEvidence.
Seconds later, there is an answer. And underneath it are sources. That sounds like another AI chatbot. It isn’t. The more interesting story is what happens after the answer.
What happens when evidence retrieval moves inside the EHR?
What happens when the answer can use patient context?
What happens when clinical evidence starts touching documentation, communication, coding, prior authorization, clinical trials, and enterprise workflows?
That is where OpenEvidence gets much more interesting. Because the company isn’t merely trying to build a smarter medical search engine. It appears to be building something much more valuable: a layer connecting medical evidence to healthcare decisions.
And that has implications far beyond individual physicians.
The $12 billion valuation was not really about a chatbot
In January 2026, OpenEvidence raised $250 million at a reported $12 billion valuation. At the time, STAT reported that the company was already free for clinicians with a National Provider Identifier and that advertising was its primary business model. The eye-catching number is the valuation. The more important number is adoption.
A June 2026 JAMA viewpoint reported that more than 40% of U.S. physicians had signed up for OpenEvidence. Becker’s, citing reporting from The New York Times, reported that OpenEvidence handled roughly 30 million questions in a single month.
OpenEvidence itself says it is used across more than 10,000 hospitals and medical centers, while its current app listing describes access to more than 35 million peer-reviewed papers and more than 300 medical journals, along with licensed content from organizations including NEJM, JAMA, Nature, Cochrane and NCCN.
That changes the question. The question is no longer: “Is OpenEvidence another medical AI tool?”
The better question is: “What happens when hundreds of thousands of clinicians become accustomed to having evidence on demand?” That is a much bigger business story.
First: What Does OpenEvidence Actually Do?
At its core, OpenEvidence is a clinical question-answering and evidence retrieval platform. A clinician asks a medical question in natural language. The system generates an answer grounded in medical sources and provides citations that allow the clinician to inspect the underlying evidence. Its current product also advertises features such as EvidenceGrade, ambient documentation through Visits, secure clinician communications through Dialer, and voice-based interaction.
Its content relationships are particularly important. OpenEvidence lists official AI relationships with NEJM, JAMA Network, Nature, Cochrane and NCCN, along with collaborations involving organizations such as the American College of Cardiology, American Diabetes Association, American Academy of Family Physicians and others. That creates a fundamentally different proposition from:
“Ask a general-purpose AI what it thinks.” The workflow is closer to: Question → evidence retrieval → synthesis → citations → clinician verification → decision. And that distinction becomes extremely important once a healthcare organization starts thinking about AI at enterprise scale.
The real OpenEvidence opportunity is a three-layer stack
Most people stop at the first layer. Businesses shouldn’t.
Layer 1: Find the evidence
This is the part everyone understands. A physician can ask:
- What does the latest evidence say about this treatment?
- How effective is this intervention for this population?
- What are the major risks?
- What guidelines apply?
- What does the literature say about a specific clinical scenario?
This is where OpenEvidence’s citation-based experience is valuable. But evidence alone isn’t the final product. It is the raw material.
Layer 2: Apply evidence to context
This is where things become much more interesting.
Cedars-Sinai announced an enterprise deployment in which clinicians could query medical literature with relevant information from an individual patient’s electronic health record. That is a major architectural shift. The question changes from:
“What does the literature say about condition X?” to: “What does the literature say, considering this patient’s clinical context?”
And those are not the same question. The second one has significantly more operational value.
Layer 3: Turn evidence into workflow
This is the layer enterprises should watch most closely. Sutter Health announced that OpenEvidence would be available inside Epic workflows so physicians could access clinical guidelines, studies and evidence through natural-language searches without leaving their existing environment.
Mount Sinai announced an enterprise-scale deployment across its clinical workforce.
Then, in September 2026, Memorial Sloan Kettering announced an integration bringing OpenEvidence into its Epic workflow while also integrating MSK’s OncoKB precision-oncology knowledge base into OpenEvidence. That is no longer simply “AI search.” It starts looking like clinical infrastructure.
What can a small healthcare business actually do with OpenEvidence?
This is where many articles get lazy. They say: “Small practices can save time.”
That means almost nothing. Let’s make it operational. Imagine a 10-provider primary care practice. The practice doesn’t need to build an AI research department. It can build an evidence workflow.
1. Clinical evidence lookup
Instead of repeatedly searching multiple medical resources for focused clinical questions, providers can use OpenEvidence as a first-pass evidence retrieval layer.
The objective isn’t to outsource clinical judgment. The objective is to reduce the time required to locate relevant evidence.
2. Faster onboarding for clinicians
A growing clinic has an unusual problem. New providers need to learn the organization’s workflows while simultaneously dealing with a huge amount of clinical knowledge.
An evidence platform can become part of the organization’s clinical learning workflow:
Question → evidence → source review → discussion → local protocol
That is much more useful than handing a new physician a 200-page PDF.
3. Specialty-specific evidence workflows
A behavioral health practice, oncology clinic, cardiology group or primary care organization can create recurring evidence-review workflows around the questions its clinicians actually encounter. For example:
Behavioral health
“What’s the current evidence around treatment-resistant depression after failure of first-line therapy?”
Primary care
“What does current evidence say about screening and management for this risk profile?”
Specialty care
“What are the latest evidence-supported treatment options for this patient population?”
The point is not that OpenEvidence makes the decision. The point is that it can shorten the path to the evidence used to inform that decision.
4. Clinical education
Instead of generic training sessions, a practice can turn recurring clinical questions into internal learning material. That creates a loop: Real question → evidence → internal education → standardized workflow
That is where a free clinician tool can become valuable to a small business.
The bigger opportunity: healthcare SaaS companies
This is where things get much more interesting for B2B businesses. Consider a healthcare software company building:
- an EHR
- a telehealth platform
- a specialty workflow application
- a patient engagement system
- a clinical dashboard
- a care-management platform
- a population-health product
- an RCM platform
- a clinical documentation product
The company doesn’t necessarily need “another chatbot.” It needs to answer a harder question:
Where should evidence appear inside the workflow? Imagine a care-management application where a clinician sees: Patient risk → relevant clinical context → supporting evidence → recommended workflow → documentation
Now the AI isn’t sitting in a separate browser tab. It is attached to the actual work. That is the strategic difference.
The enterprise version is where OpenEvidence gets scary
Small practices can use a tool. Enterprises can architect around a tool. Those are different things. Consider a large health system.
- It has physicians.
- Nurses.
- Pharmacists.
- Therapists.
- EHR systems.
- Clinical guidelines.
- Internal protocols.
- Specialty knowledge.
- Research databases.
- Patient records.
- Revenue-cycle workflows.
- Prior authorization.
- Documentation.
- Compliance.
- And thousands of people making decisions every day.
The enterprise opportunity is therefore not: “Give everyone access to OpenEvidence.”
It is: “Put evidence at the exact point where decisions are being made.”
That is what makes the EHR integrations strategically important. Sutter’s announcement focused on bringing natural-language access to clinical evidence directly into Epic. Cedars-Sinai went further by describing patient-contextualized access to medical literature at enterprise scale.
MSK is combining OpenEvidence with its own precision-oncology knowledge base, OncoKB, inside an Epic-based clinical workflow. Notice the pattern. OpenEvidence brings broad external evidence.
The healthcare organization brings proprietary institutional knowledge.
The EHR supplies patient context. The workflow supplies the action. That creates a much more powerful architecture: External Evidence + Institutional Knowledge + Patient Context + Workflow
That is the real enterprise play.
The Most Interesting Business Model May Not be the AI Answer
Here is the part many OpenEvidence articles overlook.
OpenEvidence’s current model is built around giving clinicians access for free while monetizing physician attention through advertising and building enterprise relationships. STAT reported in January 2026 that advertising was its primary business model at that point.
That is strategically important.
Because healthcare information has an unusual property:
The closer you get to the clinical decision, the more commercially valuable the attention becomes.
A physician reading a random healthcare article is one thing.
A physician researching a treatment decision is another.
That explains why OpenEvidence’s model has attracted enormous investor interest, and why the business model itself deserves scrutiny.
A 2026 JAMA viewpoint specifically examined advertising in AI-powered clinical decision-support tools, highlighting the policy and trust questions created when commercial messaging sits near high-stakes clinical decision-making.
For enterprises, that means governance matters just as much as functionality.
OpenEvidence is powerful. That does not mean it is infallible.
This is the section a credible healthcare IT company cannot skip.
A systematic review published in npj Digital Medicine in 2026 found that OpenEvidence generally generated clinically relevant, evidence-supported responses and had lower fabricated-citation rates than general-purpose models in the studies reviewed. But performance varied in complex scenarios, and the researchers emphasized that the evidence base remains limited and heterogeneous.
Then came an important independent benchmark.
A 2026 Nature Medicine study compared OpenEvidence and UpToDate Expert AI with several frontier general-purpose models. The frontier models outperformed the specialized clinical tools across the study’s evaluations.
That does not prove OpenEvidence is useless.
It proves something more important:
“Evidence-grounded” is not the same thing as “always correct.”
That distinction should shape enterprise deployment.
OpenEvidence should be treated as a clinical decision-support capability, not an autonomous clinical decision-maker.
Human review, organizational policies, clinical governance and appropriate validation remain essential.
OpenEvidence itself currently reports HIPAA and SOC 2 Type II certifications through its trust center.
But compliance certification is only one part of enterprise readiness.
The real questions are:
- What data enters the system?
- Under what contractual terms?
- Where does that data flow?
- What gets logged?
- What gets retained?
- How does the organization evaluate answer quality?
- What happens when the evidence is ambiguous?
Those questions belong in procurement and architecture, not after deployment.
The OpenEvidence SMB-to-Enterprise Opportunity Map
| Business type | High-value opportunity | What changes operationally |
| Independent clinic | Evidence lookup + clinical education | Less time spent hunting for evidence |
| Multi-provider practice | Standardized evidence workflows | More consistent internal processes |
| Specialty practice | Specialty-specific evidence retrieval | Faster access to relevant literature |
| Behavioral health organization | Evidence-supported care research | Faster clinical knowledge access |
| Healthcare SaaS startup | Evidence-aware workflow design | Clinical context becomes part of product UX |
| Digital health company | Evidence inside clinician workflows | Less context switching |
| Hospital | EHR-integrated clinical evidence | Evidence closer to point of care |
| Health system | Patient-contextualized evidence | External evidence + patient data |
| Academic medical center | Institutional knowledge + external literature | Local expertise becomes reusable |
| Life-sciences company | Clinical-trial and treatment-information workflows | Research can move closer to clinical practice |
The key takeaway? The smaller the organization, the more OpenEvidence looks like a productivity tool. The larger the organization, the more it starts looking like infrastructure.
That distinction is commercially important.
The “Evidence-to-Action” Framework
Here’s a simple way healthcare organizations can evaluate any OpenEvidence initiative.
1. Evidence
Can the system help clinicians find trustworthy, relevant evidence quickly?
2. Context
Can that evidence be understood in the context of the actual patient, specialty, organization or workflow?
3. Action
Can the resulting insight move into the workflow without forcing clinicians to copy, paste and re-enter information?
If the answer is only Evidence, you have a useful search tool.
If you have Evidence + Context, you have clinical decision support.
If you have Evidence + Context + Action, you potentially have a healthcare workflow platform.
That is the line enterprises should watch.
The hidden bottleneck: integration
There is an uncomfortable reality here. Healthcare organizations don’t need another isolated AI tab. They already have too many. The difficult part is connecting AI to the systems that run the organization.
- EHRs.
- FHIR APIs.
- HL7 interfaces.
- Identity.
- Clinical data.
- Patient portals.
- Scheduling.
- Billing.
- Payers.
- Analytics.
- Internal databases.
- Security.
- Audit trails.
That is why the OpenEvidence enterprise story is really an interoperability story.
A powerful evidence model without the right integration remains a browser tool.
A good evidence model embedded into the right workflow can become infrastructure.
This is exactly where healthcare engineering becomes critical.
CapMinds, for example, works across healthcare APIs, EHR integration, healthcare interoperability, data platforms, practice-management workflows and healthcare application development, precisely the surrounding technical layer required to operationalize clinical technology at scale.
And there is one more OpenEvidence opportunity businesses should watch
OpenEvidence is increasingly moving beyond the original “ask a medical question” experience.
Its current product listing includes ambient documentation, secure clinician communications, evidence grading, and voice interaction.
Its enterprise relationships are expanding into patient-contextualized workflows and specialty knowledge.
Its partnership with Veeva is aimed at using AI to improve areas including clinical-trial access and understanding and adoption of approved medicines.
That means the long-term story may not be:
“OpenEvidence answers medical questions.”
It may become:
“OpenEvidence sits between medical knowledge and the actions healthcare organizations take.”
That is a much bigger category.
What should healthcare SMBs do right now?
Don’t buy into the hype blindly.
Don’t ignore it either.
A smart small healthcare business should start by asking:
Which clinical decisions require the most research?
Where are clinicians losing time searching for evidence?
Which workflows repeatedly require the same clinical knowledge?
Could evidence retrieval be standardized?
What information should never leave the organization’s approved environment?
Would integrating evidence into an existing workflow create measurable value?
For many organizations, the answer will not be “deploy OpenEvidence everywhere.”
It might be:
Start with a controlled clinical use case. Measure it. Govern it. Then integrate it.
That is a much safer path than simply handing everyone an AI login.
And what should enterprises do?
Think beyond the AI tool.
Build an AI clinical architecture strategy.
That strategy should include:
Clinical evidence layer
What sources does the organization trust?
Context layer
What patient and organizational information can safely be used?
Workflow layer
Where does the resulting intelligence appear?
Integration layer
How does it connect with EHRs, APIs, FHIR, HL7 and surrounding systems?
Governance layer
Who validates, monitors and approves AI behavior?
Measurement layer
What proves the system actually improves the workflow?
The organization that gets all six right will have a far stronger AI strategy than the organization with the largest collection of AI subscriptions.
Frequently Asked Questions
What is OpenEvidence?
OpenEvidence is an AI-powered clinical information and decision-support platform that allows verified healthcare professionals to ask clinical questions and receive answers grounded in medical evidence and citations. Its current platform also includes capabilities beyond clinical search, including EvidenceGrade, Visits, Dialer and voice interaction.
Is OpenEvidence the same as ChatGPT?
No. OpenEvidence is purpose-built around clinical evidence retrieval and medical knowledge, with licensed and curated medical content. That does not automatically make it more accurate than every general-purpose AI system; independent 2026 research found frontier models outperformed OpenEvidence on several benchmarks.
Can small medical practices use OpenEvidence?
Yes, where eligible clinician access is available. The most useful applications for small practices are focused evidence retrieval, clinical education and reducing time spent searching across multiple sources. It should support, not replace, clinical judgment.
Can hospitals integrate OpenEvidence into an EHR?
Enterprise EHR deployments are already happening. Sutter Health announced integration into Epic workflows, Mount Sinai announced enterprise deployment, Cedars-Sinai described patient-contextualized use, and MSK announced Epic integration alongside OncoKB integration.
Is OpenEvidence safe for enterprise healthcare use?
OpenEvidence currently lists HIPAA and SOC 2 Type II through its Trust Center. However, enterprise suitability depends on the specific deployment, contractual terms, data handling, organizational policies, governance and validation process, not simply the existence of a certification.
The Bottom Line
OpenEvidence is interesting because it solves a very old healthcare problem with a very new interface:
There is too much medical knowledge, and clinicians don’t have enough time to retrieve it.
But its real potential is one level deeper.
When that evidence becomes connected to:
patient context
- institutional knowledge
- EHR workflows
- clinical operations
- enterprise systems
it stops being merely a search experience.
It becomes part of the infrastructure connecting knowledge to action.
And that is the opportunity healthcare businesses, from a 5-provider specialty clinic to a 50-hospital health system, should be thinking about now.
Thinking about putting clinical AI inside your healthcare workflow?
The hard part isn’t choosing an AI tool.
It’s connecting the tool to the systems, data, EHR workflows, APIs, and governance model that make it useful in production.
CapMinds helps healthcare organizations evaluate and engineer the technology layer around EHRs, interoperability, healthcare APIs, applications, automation, and clinical workflows.
